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only approximate real-life clinical practice; however, the carefully constructed model
and selection of input parameters, combined with data based directly on a post-hoc 
analysis of a clinical trial, make this a useful contribution to the debate regarding the 
incremental beneﬁ t of intensive statin therapy.
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OBJECTIVES: To assess the ﬁ nancial impact of a comprehensive cardiac care (CCC) 
program on total health care expenditures after an initial coronary event. METHODS:
This was a matched, retrospective analysis of a nurse- and pharmacist-managed CCC 
program that was designed to provide evidence-based lifestyle and medication support 
at the earliest opportunity after a coronary event. Patients with an incident occlusive 
CAD event between January 1999 and June 2004 were categorized into intervention
and comparator groups, respectively, by enrollment or never enrollment (No CCC)
into the CCC. Patients were matched 1:1 on chronic disease score (CDS) and 180-day
pre-coronary event (baseline) total health care expenditures. Pharmacy and medical 
utilization events were extracted from electronic administrative and claims databases.
Utilization events were collected after the initial coronary event until death, health 
plan termination, three years, or December 31, 2005, whichever came ﬁ rst (follow-up). 
Expenditure estimates from the Kaiser Permanente Decision Support System (in 2007 
dollars) were applied to utilization events. An intervention cost of $1/follow-up-day 
was applied to all CCC patients. Expenditures/day were modeled with adjustment 
for matching variables, patient characteristics, baseline expenditures, and intra-
correlations of matched patients. RESULTS: A total of 628 CCC patients were 
matched to 628 No CCC patients. Patients in the No CCC group were slightly older, 
more likely to be female, and to have had a myocardial infarction. Mean/median 
baseline expenditures and CDS were equivalent. During follow-up, 12 and 98 cardiac-
related deaths occurred in and mean/median total health care expenditures/day were 
$57/$30 and $159/$45 for the CCC and No CCC groups, respectively (both p 
0.001). After adjustment, CCC patients were associated with $103/day lower total 
health care expenditures (p  0.001; adjusted R-square  0.71 with log-transformed 
expenditures). CONCLUSIONS: Comprehensive and aggressive implementation of 
secondary cardiac prevention strategies with close monitoring and follow-up of CAD
patients is associated with reduced health care expenditures.
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OBJECTIVES: Venous thromboembolism (VTE) causes signiﬁ cant morbidity and
mortality and represents a huge health economic burden. Although enoxaparin has
some advantages over unfractioned heparin (UFH), both are recommended for pro-
phylaxis of VTE according to the guidelines from the Brazilian Medical Association. 
We present a tool to aid in selecting among similarly effective agents for VTE prophy-
laxis. The costs of UFH and enoxaparin to prevent venous thromboembolism in 
medical patients in the Brazilian treatment environment were compared. METHODS:
A decision model was used in a pharmacoeconomic comparison of enoxaparin and
UFH, each given for seven days, for the prophylaxis of VTE in medical patients. In
the model four main outcome pathways could follow prophylaxis: major bleeding, 
proximal deep venous thrombosis (with or without pulmonary embolism), distal deep 
venous thrombosis (DVT), and no DVT. False-negative or false-positive clinical diag-
noses of VTE were also taken into account. Probabilities of thromboembolic events 
and major bleeding were derived from published randomized clinical trials and meta-
analysis. Costs were calculated using the microcosting technique and the administra-
tive health care claims database of a major Brazilian Health Maintenance Organization 
from July, 2007 to June, 2008. The claims represented a full range of health plans 
levels at different hospitals. Only the costs related to the VTE prophylaxis and adverse 
events, acute VTE diagnosis, treatment and complications were considered. RESULTS:
Enoxaparin dominated UFH. There were cost savings of 74,121 Brazilians reais per
1,000 patients by using enoxaparin instead of UFH for prophylaxis of VTE. The
base-case analysis also demonstrated that the extra costs in the UFH group were
mainly related to the management of hemorrhagic adverse events. CONCLUSIONS:
This model of enoxaparin versus UFH for VTE prophylaxis in medical patients
showed that enoxaparin was less costly than UFH in overall expected costs from the
hospital perspective.
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OBJECTIVES: To determine the effect of a formulary change in the statin drug class 
on health outcomes and disease-speciﬁ c health care costs. METHODS: A retrospective
cohort design was implemented using pharmacy and medical claims data from a large
national employer group. Patients (n  330)with one or more claims for atorvastatin
or another statin during the six months prior to a formulary change on January 1, 
2006 were identiﬁ ed and evaluated. The formulary change was implemented for all
patients however, only those patients taking atorvastatin were affected. Cardiac-
related medical events (tests, doctor visits, outpatient facility visits, and acute cardio-
vascular events) and disease-speciﬁ c costs during the year following the formulary
change were measured. The impact of formulary change on cardiac-related medical 
events and disease-speciﬁ c costs were evaluated using multivariate analysis controlling 
for gender, age, comorbidity status, and drug indication (primary vs. secondary pre-
vention). RESULTS: Of the 330 patients, 180 (55%) used atorvastatin prior to the 
formulary change. After the implementation of the formulary change, 146 (81%) of 
patients switched to a preferred statin drug, 19 (10%) discontinued statin therapy, 
and 16 (9%) continued taking atorvastatin as a non-preferred drug. There were no
signiﬁ cant differences in the proportions of patients with cardiac tests (p  0.70), 
doctor’s visits (p  0.64), outpatient facility visits (p  0.52), or acute cardiovascular 
events (p  0.13) in the year after the formulary change between patients with pre-
formulary change claims for atorvastatin or another statin. There were no statistically
signiﬁ cant differences in health care costs among patients with pre-formulary change
claims for atorvastatin or another statin after adjustment for covariates (OR  0.89, 
95% CI: 0.41–1.92). CONCLUSIONS: Changing the formulary status of atorvastatin 
does not appear to adversely affect the total medical costs or utilization of cardiac-
related health care services.
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OBJECTIVES: Edaravone (Radicut), which was ﬁ rst approved in Japan in June 2001 
as a free radical scavenger, is used widely for the treatment of acute ischemic stroke 
in Japan. The purpose of this study was to estimate the economic impact of edaravone
therapy in Japan based on results of a meta-analysis of edaravone therapy for patients 
with lacunar infarction. METHODS: Japanese patients with lacunar infarction aged 
35 years or older were included in this analysis. We compared the economic impact 
of treatment for lacunar infarction between the edaravone group (E group) and the 
non-edaravone group (non-E group). For the basic information on patient status for
this analysis, we used previously published meta-analysis data on the modiﬁ ed Rankin 
Scale (mRS) distribution 1 month or more after the occurrence of lacunar infarction. 
Four types of costs were considered: hospitalization costs for lacunar infarction
therapy, nursing-care costs after hospital discharge, and productivity costs during 
hospitalization and due to work loss. RESULTS: The total costs per patient with 
lacunar infarction in the E and non-E groups were US$42,054 (1US$  92 JPY) and 
US$47,270, respectively, and the potential cost savings for using edaravone therapy
was estimated at US$5,216. The breakdown of total costs in the E and non-E groups, 
respectively were for hospitalization costs: US$10,215 (24.3%), and US$8,150
(17.2%), nursing-care costs: US$14,779 (35.1%), and US$18,256 (38.6%), decreased
productivity costs due to hospitalization: US$1,956 (4.7%), and US$2,065 (4.4%), 
and those due to work loss: US$15,105 (35.9%), and US$18,691 (39.5%). CONCLU-
SIONS: In this analysis, edaravone therapy for patients with lacunar infarction was 
ultimately a promising cost saving therapy compared with other therapies that did not
use edaravone, as it avoided nursing-care costs and productivity loss despite being
more expensive during acute treatment.
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OBJECTIVES: To assess the cost-effectiveness of oral rivaroxaban versus subcutane-
ous enoxaparin for prevention of venous thromboembolism (VTE) following total hip
replacement (THR) or total knee replacement (TKR) in Korea. METHODS: An eco-
nomic model was developed to evaluate the clinical and economic consequences of 
rivaroxaban versus enoxaparin, based on the RECORD2 and 3 randomized controlled 
trials. RECORD2 compared a 35-day course of rivaroxaban with a 12-day course of 
enoxaparin in THR, while RECORD3 compared 12-day courses of rivaroxaban and 
enoxaparin following TKR. In RECORD2, rivaroxaban reduced total VTE (compos-
ite: any deep vein thrombosis, non-fatal pulmonary embolism and all-cause mortality) 
by 79% and symptomatic VTE by 80% versus 12-day enoxaparin. In RECORD3,
rivaroxaban reduced total VTE by 49% and symptomatic VTE by 66% versus enoxa-
parin. Occurrence of major bleeding was similar with both agents. The model
accounted resource use according to primary research data and included direct medical 
costs from the Korean Health Insurance Review Agency. Utilities were derived from 
published literature and clinical and economic outcomes were discounted at a 5% 
annual rate in line with Korean guidelines. The model reported effectiveness outcomes
in quality-adjusted life years (QALYs) and costs in Korean Won (KRW) and was run 
over a ﬁ ve-year time horizon. RESULTS: In THR, rivaroxaban demonstrated per-
patient cost savings of KRW 40,803 versus enoxaparin and a gain of 0.0027 QALYs
per patient. In TKR, rivaroxaban reduced per-patient costs by KRW 27,692 and 
resulted in a gain of 0.0019 QALYs per patient. Cost savings in the rivaroxaban arm 
